Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab

SHASHA LV1, ERIK TEUGELS1, JAN SADONES1,2, SYLVIA DE BRAKELEER1, JOHNNY DUERINCK1,4, STEPHANIE DU FOUR1,4, ALEX MICHOTTE2,3, JACQUES DE GRÈVE1 and BART NEYNS1

1Laboratory of Molecular Oncology and Department of Medical Oncology, Departments of 2Pathology, 3Pathology and Neuropathology and 4Neurosurgery, University Hospital Brussels, Free University Brussels, 1090 Brussels, Belgium

Received March 9, 2012; Accepted April 27, 2012

DOI: 10.3892/ijo.2012.1539

Abstract. Mutation and gene amplification of the epithelial growth factor receptor (EGFR) is one of the most common genetic alterations in glioblastoma (GB). EGFR is, therefore, an attractive molecular target for the treatment of GB. EGFR-targeted therapies however have been largely ineffective in clinical trials. In this study, we investigated the correlation between the EGFR gene amplification status, expression of the EGFR variant III (EGFRvIII) and EGFR variant IV (EGFRvIV) mutations, expression of the phosphatase and tensin homologue gene on chromosome 10 (PTEN) and mutation of the isocitrate dehydrogenase 1 (IDH1) gene and the survival of patients suffering from recurrent glioblastoma who were treated with the EGFR-targeted monoclonal antibody cetuximab in a prospective phase II clinical trial. EGFR amplification was detected in 19 out of 35 GB (54%), EGFRvIII expression in 11 (31.4%) and EGFRvIV expression in 7 (20%). The EGFRvIII and EGFRvIV mutations were exclusively found in GB with EGFR amplification and were almost mutually exclusive with IDH1 mutation (EGFRvIII mutation was found in 1 out of 11 GB with an IDH1 mutation). Patients with an EGFR amplification lacking EGFRvIII expression had a significantly superior progression free survival (PFS) and a numerical better overall survival (OS) following treatment with cetuximab [median PFS 3.03 vs. 1.63 months (p=0.006); median OS 5.57 vs. 3.97 months (p=0.12)]. Within the subgroup of patients with EGFR amplification, patients with EGFRvIII positive glioblastoma had a worse survival [median PFS 1.63 vs. 3.03 months (p=0.01); median OS 3.27 vs. 5.57 months (p=0.08)]. Our observations indicate that the type of EGFR mutation may determine the outcome of GB patients treated with cetuximab. Prospective investigation of both the EGFR amplification and mutation status in clinical trials with EGFR-targeted therapies for GB is indicated.

Introduction

Glioblastoma (GB, WHO grade IV glioma) and anaplastic gliomas (WHO grade III gliomas) are lethal brain tumors for which only limited therapeutic options exist. The standard treatment for high-grade gliomas (WHO grade III and IV) consists of a maximal safe surgical resection followed by adjuvant radiotherapy. While concomitant temozolomide during the radiation therapy followed by six cycles of adjuvant chemotherapy improves the survival of patients with GB, the role of chemotherapy in the initial treatment of anaplastic glioma remains to be defined (1).

Clinically relevant molecular subtypes of GB have recently been identified (2). A small proportion of GB are characterized by mutation of the isocitrate dehydrogenase 1 and -2 (IDH1 and -2) genes, a genotype that is most frequently found in low-grade and anaplastic gliomas (3). Genomic alterations of the epidermal growth factor receptor (EGFR) gene play a crucial role in pathogenesis of a subgroup of GB (4). The most common gain-of-function alterations for EGFR in GB are mutation, amplification, and overexpression (5,6). Expression of a constitutively phosphorylated EGFR-mutant, EGFR variant III (EGFRvIII), is found in approximately 20%-30% of GB patients. EGFRvIII has an in-frame deletion of exons 2-7 resulting in the loss of the amino acid residues that contribute to the ligand binding area. Consequently, EGFRvIII causes ligand-independent constitutive activation of downstream signaling pathways such as the Mitogen-activated protein kinase (MAPK) pathway that contributes to the malignant phenotype (7-9). In vitro studies have demonstrated that expression of EGFRvIII leads to a growth and survival advantage in several types of cancer cells (10-13). Another frequent EGFR mutant in GB is the EGFR variant IV (EGFRvIV), which has a genomic truncation of the carboxyl-terminal domain (CTD, exon 25, 26 and 27 in EGFRvVa or exon 25 and 26 in EGFRvVb) (14,15). Both
EGFRvIV variants have a transforming capacity in vitro and in animals (16). Furthermore, a novel deletion mutation with the transforming capacity was found also in EGFR CTD which is the deletion of exon 27 (17).

In high-grade gliomas, the EGFRvIII and EGFRvIV mutations have been found exclusively in association with EGFR gene amplification (18,19). Expression of EGFRvIII identifies a particular subtype of anaplastic astrocytoma with a poor prognosis. In the global GB-population this correlation with survival is less distinct (20-24). However, within the subpopulation of GB patients with EGFR amplification, a strong correlation was reported between EGFRvIII expression and a poor overall survival (4). No study has yet reported a correlation between EGFRvIV expression and survival of GB patients.

The importance of EGFRvIII expression as a predictive marker for anti-EGFR therapies has been a matter of debate. Co-expression of EGFRvIII and a phosphatase and tensin homologue on chromosome 10 (PTEN) was reported to be a significant predictor of responsiveness to small molecule EGFR kinase inhibitors in retrospectively identified GB patients benefitting from such therapy (25). Furthermore, concomitant EGFRvIII expression and loss of PTEN were shown to synergistically induce genomic instability in vitro and result in enhanced tumor formation (26). In additional studies it was reported that EGFR amplification and protein kinase B/akt activation to predict the response to treatment with a small molecule EGFR kinase inhibitor in GB patients (27-28). These findings were however not confirmed in a prospective randomized study with erlotinib (29).

In vitro data indicate that cetuximab is able to bind to and down regulate EGFRvIII. This may however not be sufficient to inhibit the proliferation of the glioma cells (30). Other observations have indicated that cetuximab not only reduced the phosphorylated EGFRvIII but also inhibited significantly the proliferation of EGFRvIII expressing cells (31). Moreover, cetuximab proved to be active in animal models with EGFR amplified GB (32). In addition, radiation and chemotherapeutic agents augmented the effect of cetuximab on GB cells (33). Recently, the anti-tumor activity of cetuximab against EGFR CTD-mutant GB in both cells and animals was reported (17).

We have previously reported the results of a stratified 2-arm prospective phase II clinical trial of recurrent high-grade glioma patients treated with the EGFR monocular antibody cetuximab. A numerically superior outcome, not reaching statistical significance, was found in patients with EGFR gene amplification (34). In this work, we have further investigated the correlation between EGFR amplification, EGFRvIII and EGFRvIV expression, PTEN expression, and IDH1 mutation status and the survival of patients treated with cetuximab in this clinical trial.

Materials and methods

Patients and tumor material. Tumor material was obtained from 35 patients with recurrent high-grade glioma who participated in the prospective phase II trial (34). Tumor tissues were obtained during therapeutic resections performed before the time of study participation. Tumor sections with a thickness of 4 µm were used for H&E staining and centralized review of tumor histopathology and grading according to WHO 2007 criteria (35).

EGFR and IDH1 molecular analysis. The IDH1 mutation status was assessed with a PCR-DGGE-Sequencing system as reported previously (36). The amplification status of EGFR was assessed by FISH, as described in the report on the clinical trial with cetuximab (34).

For the molecular analysis of EGFRvIII, formalin-fixed paraffin-embedded (FFPE) tissue blocks were sectioned at a thickness of 10 µm (3 sections for RNA isolation). As a positive control an EGFRvIII transfected U87 cell line, obtained from Professor Webster Cavenee (Ludwig Institute for Cancer Research, University of California, San Diego, CA, USA), was used (10). Tissues were dewaxed by xylene and ethanol. The total RNA was isolated from tumor sections using the RNeasy FFPE kit (Qiagen, Venlo, Netherlands) according to the manufacturer’s instructions with modifications by changing the incubation time after mixing with proteinase K for 36 h at 55°C, meanwhile, adding proteinase K every 12 h. Depending on the size of the tumor sample, the RNA ranged from 0.02 to 2 µg (Nanodrop2000, Thermo Scientific, Wilmington, DE, USA). The RNA isolation of the positive control cell line (U87b) was performed with the Absolute RNA Wash Solution (Applied Biosystems, Carlsbad, CA, USA). The reverse transcription was accomplished using the SuperScript® II Reverse Transcriptase (Invitrogen) according to the manufacturer's protocol. The entire cDNA sample was treated with Ribonuclease H (Invitrogen, Ghent, Belgium) to eliminate the residual RNA after reverse transcription.

Two pairs of primers for EGFRvIII were derived from the previous reference to perform a hemi-nested PCR (19) with some modifications. For the first step PCR, a forward primer GAGCTCTTCGGGGAGCAG and a reverse primer TCCCTCATGCTCG were used to generate a 178 bp fragment that span the junctions of the deletion c.158_1136del. A standard PCR Master mix (25 µl in total) is composed of cDNA (1 µl), 1X PCR buffer, 1 µg/µl bovine serum albumin (BSA), 0.8 mM dNTPs, 0.025 U/µl Taq DNA polymerase (Qiagen, 5 µl) and 2 ng/µl of each primer. The reaction was run for 35 cycles denaturation at 94°C for 1 min, annealing at 64°C for 1 min and extension at 72°C for 1 min. During the second step, a 131 bp fragment was amplified 25 cycles using 1 µl of product from the first step PCR with the forwards primer GAGCTCTTGCGGGAGCCAG and the reverse primer TCTGCATGCTCG were used to generate a 178 bp fragment that span the junctions of the deletion c.158_1136del. All other PCR conditions were the same as step 1. The final PCR product was visualized on a 2% agarose gel and confirmed by sequencing (ABI 310 Genetic Analyzer, Applied Biosystems, Foster city, CA, USA) after purification with the High Pure PCR Product Purification kit (Roche, Penzberg, Germany). The analysis of each sample was performed in triplicate. EGFRvIV mutation analysis was performed with the same method as EGFRvIII.

Immunohistochemistry of PTEN. PTEN expression was evaluated by immunohistochemistry on 4 µm FFPE tissue sections by using a rabbit IgG monoclonal antibody (1:100 dilution, PTEN, 138G6, Cell Signaling Technology Inc., Beverly, MA, USA) and an anti-rabbit IgG secondary antibody (ultraView Universal DAB Detection Kit, Ventana Medical Systems Inc.,
Tucson, AZ, USA) according to the manufacturer's protocol. Immunoreactivity was visualized with a DAB solution provided in the kit (ultraView Universal DAB Detection Kit, Ventana Medical Systems Inc.). Positive controls were visualized on the same sections with epithelial cells and neurons. PTEN staining was both nuclear and cytoplasmic and was evaluated with a two-score system including intensity and percentage of positive cells as described (37).

Clinical data and survival analysis. Clinical information was collected from each patient to investigate possible correlation between EGFRvIII mutation status and clinical parameters including glioma WHO grade, age, date of birth, date of initial diagnosis and of recurrence, date of progression and date of death or last contact. Kaplan-Meier survival analysis was used to examine the correlation between molecular baseline factors and survival data. We also analyzed the association between EGFRvIII, EGFRvIV, PTEN expression, EGFR amplification and IDH1 mutation.

Results

Analysis of EGFR gene amplification, EGFRvIII-, EGFRvIV-RNA expression, and PTEN-protein expression and IDH1 mutation status. EGFR amplification, EGFRvIII-, and EGFRvIV expression were detected in, respectively 19/35 (54%), 11/35 (31%) and 7/35 (20%, EGFRvIVa in 5/7 and EGFRvIVb in 2/7) of the gliomas (Fig. 1, Table I). EGFRvIII and EGFRvIV expression were exclusively found in patients with an EGFR amplification (11/19, 58%; 7/19, 37%). EGFRvIII was most frequently found in de novo GBs (9/26, 35%), and less frequently in secondary GBs and grade II or III glioma (2/9, 22%). Likewise, EGFRvIV was detected in 6/26 (23%) de novo GB and 1/9 (11%) of the anaplastic astrocytoma.

IDH1 mutation was found in 6/35 (17%) patients (Table I) and correlated with a younger age at first diagnosis, and a histological diagnosis of low-grade or secondary GB. IDH1 mutation was only rarely found in association with an EGFR amplification or expression of EGFRvIII and EGFRvIV (2/19 patients with EGFR amplification, 1/11 patients with EGFRvIII and 0/7 patients with EGFRvIV were found with a concomitant IDH1 mutation, Table II).

Strong positive IHC staining for PTEN expression was observed in 6 out of the 31 tested gliomas (Fig. 2) and found only in WHO grade IV gliomas (5/6 de novo GB and 1/6 secondary GB). Of these 6 patients with a PTEN positive de novo GB, 4 had an EGFR amplification, two of which also expressed EGFRvIII, none of them had EGFRvIV and all 6 patients had an IDH1 wild-type status (Table II). No significant correlation was found between PTEN expression and clinical baseline characteristics such as age, gender and performance status.
Correlation between molecular markers and the survival of patients treated with cetuximab. At the time of this analysis, 34 out of 35 patients died, all because of tumor progression; one patient was lost to follow-up. The median overall survival (OS) and median progression free survival (PFS) from the time of recruitment to the clinical trial were respectively 4.8 months (95% CI: 3.9-5.6) and 1.8 months (95% CI: 1.5-2.0) (Table II).

In our previous report on this phase II trial, EGFR amplification was found to correlate with a numerical superior PFS and OS in patients treated with cetuximab (34). In this updated subgroup analysis, the correlation between EGFR amplification and superior survival of patients was still present for PFS [median PFS 2.10 in patients with EGFR amplification vs. 1.63 in patients with wild-type EGFR (p=0.09)] (Fig. 3A), however, was no longer found for OS [median OS 4.73 in patients with EGFR amplification vs. 4.80 in patients with wild-type EGFR, p=0.69). A numerically worse survival (PFS and OS) was observed for patients with expression of EGFRvIII but this difference did not reach the level of statistical significance [median PFS of 1.63 vs. 1.93 months (p=0.21) and median OS of 3.27 vs. 4.93 months (p=0.21)] (Fig. 3B and C). A better PFS and OS were found for patients with EGFR amplification lacking EGFRvIII expression [median PFS of 3.03 vs. 1.63 months (p=0.006); median OS of 5.57 vs. 3.97 months (p=0.12)] (Fig. 3D and E). When analyzed within the cohort of patients with EGFR amplification (n=19), expression of EGFRvIII correlated significantly with a worse outcome in survival [median PFS 1.63 vs. 3.03 months (p=0.01); median OS 3.27 vs. 5.57 months (p=0.08)] (Fig. 3F and G).

In univariate analysis, EGFRvIV mutation and PTEN expression were not correlated with the survival of the total population or within the subgroup of EGFR-amplified GBs.

### Discussion

In this study of 35 patients with recurrent high-grade gliomas treated with the EGFR monoclonal antibody cetuximab, we find that EGFRvIII/vIV expression is restricted for patients with EGFR amplification, confirming prior reports in the literature. EGFRvIII and EGFRvIV expression were rarely found in patients with an IDH1 mutation (1/6 and 0/6), again confirming...
the previous reports on the association of IDH1 mutation with WHO grade II and III glioma and secondary GB (3) and EGFR amplification/mutation with \textit{de novo} GB (38).

Overall treatment with cetuximab has low activity against recurrent GB but shows a trend towards a higher activity in patients with EGFR-amplified GB, as was reported in our initial clinical study report (34). In this molecular sub-study we investigated the potential influence of specific EGFR-mutants and found that the expression of EGFRvIII correlated with a significantly worse survival in the cohort of patients with an EGFR amplification in our study. Similar observations have been reported previously (4). Since we observed that, the PFS of patients treated with cetuximab was significantly superior in patients with EGFR gene amplification but without EGFRvIII expression, we hypothesize that EGFR amplification without EGFRvIII may identify a subpopulation with a higher sensitivity for cetuximab. Given the single-arm study design, we however cannot exclude a naturally worse prognosis of EGFRvIII mutant GB among patients with EGFR-amplified tumors.

Although it was reported that cetuximab showed effective inhibition to EGFR CTD deletion mutation in glioblastoma cells and animal models (17), we did not find a correlation between EGFRvIV deletion and survival of patients in our study in total population or any sub-cohort. We can however not exclude that this is related to the small sample size of patients with an EGFRvIV mutated GB in our study.

Figure 2. Immunohistochemistry images of PTEN. (A and B) PTEN negative and positive staining on glioma tissues.

Figure 3. Kaplan-Meier survival estimates (p-value according to the Log-rank test). (A) Progression free survival (PFS) from the time of cetuximab treatment on EGFR amplification status in the global study population (p=0.09), solid line, EGFR amplification; dash line, EGFR wild-type; +, censored. (B and C) PFS and OS from the time of treatment of cetuximab in global population EGFRvIII status (p=0.21 and 0.21), solid line, EGFRvIII negative; dash line, EGFRvIII positive; +, censored. (D and E) PFS and OS from the time of treatment of cetuximab in global population based on EGFR amplification/EGFRvIII status (p=0.006 and 0.12), solid line, EGFR amplification without EGFRvIII; dash line, others; +, censored. (F and G) PFS and OS from the time of treatment of cetuximab in cohort of patients with EGFR amplification based on EGFRvIII status (p=0.01 and 0.08), solid line, EGFRvIII negative; dash line, EGFRvIII positive; +, censored.
In the literature, PTEN expression detected by IHC has been reported in about 62% of primary glioma (39) and in 17% of recurrent GB (40). PTEN expression as detected by IHC is also more frequently found in low-grade glioma as compared to high-grade glioma. We detected a positive PTEN expression in 21% of high-grade glioma (in 19% of the whole population), which is comparable with the data in the literature. It was previously reported that coexpression of EGFRvIII and PTEN was a predictor for response to EGFR inhibitors in patients with recurrent GB (25). In this study only two patients were found with combined EGFRvIII and PTEN expression making it impossible to assess this correlation. A study with larger sample size would be needed to assess the role of EGFRvIII and PTEN in survival of glioma patients treated with cetuximab at recurrence.

In summary, within the recurrent glioma patients who were treated with cetuximab we have confirmed that EGFR mutation is exclusively present in patients with EGFR amplification, but without EGFRvIII expression. Our study supports further documentation of both the glioma EGFRvIII expression and amplification status in studies with cetuximab.

Acknowledgements

This study was supported by the Free University Brussels (VUB)/the Chinese Scholarship Council (CSC) PhD program. We gratefully acknowledge the supply of U87/EGFRvIII cell from Professor Webster Cavenee (Ludwig Institute for Cancer Research, University of California, San Diego, CA, USA). We thank Mr. Kurt De Neef (Laboratory of Molecular Oncology, Free University Brussels, Belgium), Mr. Pascal Verhavert, Mr. Tim Walravens and Miss Sara Laceur (Pathology Department, University Hospital Brussels, Belgium) for their technical help. We also thank Miss Katrien Van den Bossche (data manager, University Hospital Brussels, Belgium) for her assistance and help. Bart Neyns has received research funding (data manager, University Hospital Brussels, Belgium) for her technical help. We also thank Miss Katrien Van den Bossche (data manager, University Hospital Brussels, Belgium) for their technical help. We also thank Mr. Kurt De Neef (Laboratory of Molecular Oncology, Free University Brussels, Belgium), Mr. Pascal Verhavert, Mr. Tim Walravens and Miss Sara Laceur (Pathology Department, University Hospital Brussels, Belgium) for their technical help. We also thank Miss Katrien Van den Bossche (data manager, University Hospital Brussels, Belgium) for her assistance and help. Bart Neyns has received research funding from Merck.

References